Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Lilly To Start Phase III Trials in Diabetic Peripheral Neuropathy For LY-333531

  • News

Executive Summary

Lilly is expanding its Phase III program for the protein kinase C-beta inhibitor LY-333531 to include diabetic peripheral neuropathy

You may also be interested in...



Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market

Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients

Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market

Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients

Lilly GMP “Culture Change” Will Address Compliance Issues, Firm Tells FDA

Lilly is seeking to "affect cultural change" in its approach to GMP compliance, the company assured FDA in a response to the most recent FDA-483 manufacturing report for Forteo and Zyprexa IM

Table

View full table

Tags:
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS040016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By